This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Carmen ACE, Zaneril, Zanextra (FR), Zan-Extra (AU), Zanitek, lercanidipine + enalapril fixed combination
BioMedTracker maintains separate drug profiles for the combination and single formulations of Lercanidipine. Please also see Zanidip.
Zanipress is a fixed combination of a calciym channel blocker (lercanidipine) and an ACE inhibitor (enalapril), two medicines that lower blood pressure. Zanipress is used for the treatment of high blood pressure (hypertension) in patients in whom adequate control of blood pressure cannot be achieved by treatment with lercanidipine or enalapril alone.
Recordati and Meda
In February 2007, Recordati announced that it has signed a non-exclusive agreement with Meda for the marketing and sale in Germany of Zaneril (lercanidipine and enalapril).
Meda & Rottapharm
In July 2014, Meda announced that it has entered into a definitive agreement to acquire RottapharmMadaus, an Italian company owned by the Rovati family, for a consideration of SEK 21.2 billion (2.275 billion) on a cash and debt free basis. The consideration will comprise SEK 15.3 billion (1.643 billion) in cash, 30 million Meda shares corresponding to a value of SEK 3.3 billion (357 million) and a non-contingent deferred payment in January 2017 of SEK 2.6 billion (275 million). Following completion of the transaction, the Rovati family will own 9% of Meda. The acquisition of Rottapharm must be reported to the competition authorities of multiple jurisdictions. Filings for gaining approvals will be initiated within days and the transaction is expected...See full deal structure in Biomedtracker
Partners: Pierre Fabre Medicament S.A. The Menarini Group Mylan Inc.
Additional information available to subscribers only: